Prediction of Erosive Disease in Early Rheumatoid Arthritis (RA) by Ultrasound and Cartilage Biodegradation Markers
NCT ID: NCT02464384
Last Updated: 2015-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
24 participants
INTERVENTIONAL
2016-04-30
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary objectives:
* Correlation of ultrasound synovitis score and clinical disease activity score
* Determination of the sensitivity of ultrasound erosion detection compared to MRI
* Assessment of the value of including tenosynovitis assessment for predicting radiographic progression
* Assessment of the predictive value of ultrasound synovitis score at baseline for the need to install biologic DMARDs
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Duration of study: 12 months This study is a prospective cohort study. The choice of therapy at any time during the study is entirely up to the treating rheumatologist. The study does not put any restriction on the management of the patient which will be according to routine care.
At occurrence of one or more of the above mentioned variables defining adverse clinical outcome (prednisone in a dose exceeding 10mg/d and/or intraarticular steroid injections and/or start of biologic DMARD) an analysis as for D360 will be performed US-Score: SONAR-Score assessment of synovitis (22 joints)/erosions (14 joints)/cartilage thickness (8 joints) Clinical evaluation: Disease activity score (DAS28 = Number of tender and swollen joints (0-28), additional measures (ESR / CRP), Patient Global Health (0-100), health assessment questionnaire (HAQ) at 0, 3, 6, 9, 12 months (attached) Lab: ESR, CRP Serology: Antinuclear antibody (ANA), Rheumatoid factor (RF), Anti-cyclic citrullinated peptide (anti-CCP) at baseline if not available COL2-1 / COL2-1N X-Ray: hands and feet at baseline and 12 months (scoring according to Ratingen Score) if not available MRI without contrast at baseline and at 12 months or when first erosions detected with US
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cohort study
Collection of blood samples and ultrasound / MRI and x-ray examination.
Venipuncture, ultrasound, MRI, x-ray
Collection of blood samples and ultrasound / MRI and x-ray examination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venipuncture, ultrasound, MRI, x-ray
Collection of blood samples and ultrasound / MRI and x-ray examination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* recent onset RA fulfilling the American College of Rheumatology (ACR) criteria (revised 2010)
* Symptoms for at least 6 weeks
* no previous DMARD treatment
* no intraarticular steroid injections in the last 4 weeks before inclusion
* no treatment with oral steroids exceeding the equivalent of 10mg prednisone per day in the last 2 weeks before inclusion
* signed Informed Consent after being informed
Exclusion Criteria
* History of active Tbc, histoplasmosis or listeriosis
* History of lymphoma or other malignancies within 5 years
* Contraindication for the use of DMARD's or biologics
* Comorbidities: severe myocardial dysfunction, recent stroke (within 3 months), uncontrolled diabetes and other disease which in the opinion of the investigator, would put the subject at risk by participation in the trial
* History of demyelinating disorders
* persistent or recurrent infections
* Pregnancy or breast feeding
* no informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian Ciurea, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Rheumatology, University Hospital Zurich
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UPEDRA01_01.07.2013
Identifier Type: -
Identifier Source: org_study_id